The North America Competent Cells Market would witness market growth of 7.3% CAGR during the forecast period (2024-2031).
The US market dominated the North America Competent Cells Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $898.8 million by 2031. The Canada market is experiencing a CAGR of 9.4% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 9.4% during (2024 - 2031).
These cells, particularly Escherichia coli (E. coli) and other bacterial strains have a wide range of applications across various fields within biotechnology, pharmaceuticals, agriculture, and research. These cells are essential for molecular cloning techniques, where they are used to introduce foreign DNA into bacterial cells. This process involves transforming these cells with recombinant DNA molecules, typically carried on plasmids or other vectors. Cloning allows researchers to replicate and study specific DNA sequences, gene functions, and regulatory elements.
These cells serve as hosts for gene expression studies, enabling the production of proteins encoded by cloned genes. Researchers can induce the expression of recombinant proteins in these cells to study protein structure, function, and interactions. This application is crucial for pharmaceutical research, engineering, and therapeutic protein production. These cells are crucial in constructing and screening genomics, cDNA, and protein libraries. These libraries contain cloned DNA fragments or expressed genes, which serve as valuable resources for identifying novel genes, biomarkers, drug targets, and therapeutic candidates.
As pharmaceutical companies in Canada intensify their research efforts, there will be a higher demand for these cells used in genetic engineering and drug development processes. According to Statistics Canada, in 2020, the R&D pharmaceutical sector contributed $15.9 billion to the Canadian economy in GVA, an increase of 5.8% from the $15.0 billion generated in 2019. Just under half of this ($7.9 billion) was attributable to the direct impacts of the sector, which rose 4.5% from the $7.6 billion generated in 2019. Furthermore, The Mexican government, through agencies like CONACYT (Consejo Nacional de Ciencia y Tecnología), provides research grants and funding opportunities specifically targeted at biotechnology and life sciences. These funds support research projects that require these cells for applications such as genetic engineering, biopharmaceutical development, and agricultural biotechnology. Therefore, rising R&D in pharmaceutical industry and rising government initiative are propelling the growth of the market.
Free Valuable Insights: The Competent Cells Market is Predict to reach USD 3.7 Billion by 2031, at a CAGR of 7.9%
Based on Type, the market is segmented into Chemically Competent Cells, Electrocompetent Cells, and Ultracompetent Cells. Based on Application, the market is segmented into Cloning, Protein Expression, Mutagenesis, and Others. Based on End-Use, the market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
By Type
By Application
By End-Use
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 